Seemann Marcus D, Meisetschlaeger G, Gaa J, Rummeny E J
Department of Nuclear Medicine, Technical University, Munich, Ismaninger Strasse 22, D-81675 Munich, Germany.
Eur J Med Res. 2006 Feb 21;11(2):58-65.
To assess the diagnostic value of whole-body positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI), and the fusion of PET and CT (PET/CT) and PET and MRI (PET/MRI) in the detection of metastatic disease of gastrointestinal carcinoid tumors.
This prospective study included six patients with extensive nonresectable metastases of gastrointestinal carcinoid tumors which were consecutively examined from the base of the skull to the proximal thigh using a state-of-the-art PET/CT scanner and a 1.5 Tesla whole-body MRI scanner. PET was performed with a carbohydrated F-18-labeled somatostatin-receptor ligand ([ superset18 F]FP-Gluc-TOCA) using a Pico-3D PET scanner. CT was performed with a venous-dominant contrast-enhanced phase using a 16-slice CT scanner. MRI was performed with a coronal T2-weighted Half-Fourier Acquired Single-Shot Turbo Spin Echo (HASTE) sequence, a coronal T2-weighted Turbo-Short Tau Inversion-Recovery (STIR) sequence, a coronal T1-weighted Turbo Spin Echo (TSE) sequence and a high resolution axial T2-weighted TSE sequence. The data sets from PET and CT were fused automatically. The PET and MRI data sets were fused manually. Lesions were rated as metastases if they were not clearly identified as benign lesions according to standard radiological criteria.
For PET, CT, MRI, PET/CT, and PET/MRI, the lesion-by-lesion based analysis showed an overall detection rate for liver metastases (n = 391) of 49.9% (P<.001), 37.1% (P<.001), 98.2%, 50.9% (P<.001) and 100%, for lymph node metastases (n = 37) of 91.9%, 83.8%, 64.9%, 100% and 97.3% and for osseous metastases (n = 12) of 100%, 8.3% (P<.005), 66.7%, 100% and 100%.
PET as single modality revealed the most lymph node and osseous metastases. MRI as single modality revealed the most liver metastases. The combination of molecular/metabolic with anatomical/ morphological information improves the diagnostic accuracy for the detection of metastases in comparison to the single modalities. Whole-body PET/MRI is a very promising diagnostic modality for oncological imaging due to the missing radiation exposure and the high soft tissue resolution of MRI in contrast to CT.
评估全身正电子发射断层扫描(PET)、计算机断层扫描(CT)、磁共振成像(MRI)以及PET与CT融合(PET/CT)和PET与MRI融合(PET/MRI)在检测胃肠道类癌肿瘤转移疾病中的诊断价值。
这项前瞻性研究纳入了6例胃肠道类癌肿瘤广泛不可切除转移的患者,使用先进的PET/CT扫描仪和1.5特斯拉全身MRI扫描仪,从颅底至大腿近端进行连续检查。PET采用碳水化合物F-18标记的生长抑素受体配体([18F]FP-Gluc-TOCA),使用Pico-3D PET扫描仪进行检查。CT采用静脉主导的对比增强期,使用16层CT扫描仪进行检查。MRI采用冠状面T2加权半傅里叶采集单次激发快速自旋回波(HASTE)序列、冠状面T2加权快速短反转恢复(STIR)序列、冠状面T1加权快速自旋回波(TSE)序列和高分辨率轴向T2加权TSE序列。PET和CT的数据集自动融合。PET和MRI的数据集手动融合。根据标准放射学标准,若病变未明确判定为良性病变,则将其评定为转移灶。
对于PET、CT、MRI、PET/CT和PET/MRI,基于逐个病变的分析显示,肝转移灶(n = 391)的总体检出率分别为49.9%(P<0.001)、37.1%(P<0.001)、98.2%、50.9%(P<0.001)和100%;淋巴结转移灶(n = 37)的总体检出率分别为91.9%、83.8%、64.9%、100%和97.3%;骨转移灶(n = 12)的总体检出率分别为100%、8.3%(P<0.005)、66.7%、100%和100%。
PET作为单一检查手段显示出最多的淋巴结和骨转移灶。MRI作为单一检查手段显示出最多的肝转移灶。与单一检查手段相比,分子/代谢信息与解剖/形态学信息的结合提高了转移灶检测的诊断准确性。与CT相比,全身PET/MRI由于无辐射暴露且MRI具有高软组织分辨率,是一种非常有前景的肿瘤影像学诊断手段。